Abstract

Existing assays to measure antibody cross-reactivity against different SARS-CoV-2 spike (S) protein variants lack the discriminatory power to provide insights at the level of individual clones. Using a mass spectrometry-based approach we are able to monitor individual donors’ IgG1 clonal responses following a SARS-CoV-2 infection. We monitor the plasma clonal IgG1 profiles of 8 donors who had experienced an infection by either the wild type Wuhan Hu-1 virus or one of 3 VOCs (Alpha, Beta and Gamma). In these donors we chart the full plasma IgG1 repertoires as well as the IgG1 repertoires targeting the SARS-CoV-2 spike protein trimer VOC antigens. The plasma of each donor contains numerous anti-spike IgG1 antibodies, accounting for <0.1% up to almost 10% of all IgG1s. Some of these antibodies are VOC-specific whereas others do recognize multiple or even all VOCs. We show that in these polyclonal responses, each clone exhibits a distinct cross-reactivity and also distinct virus neutralization capacity. These observations support the need for a more personalized look at the antibody clonal responses to infectious diseases.

Profiling antibody repertoires using proteomic approaches may provide a way of screening for antibody cross-reactivity against SARS-CoV-2 variants. Here the authors use a IgG1 specific cleavage method to analyse the IgG1 repertoire within recovered patients and relate this to antibody binding and neutralisation.

Details

Title
Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
Author
van Rijswijck, Danique M. H. 1   VIAFID ORCID Logo  ; Bondt, Albert 1   VIAFID ORCID Logo  ; Hoek, Max 1 ; van der Straten, Karlijn 2 ; Caniels, Tom G. 3   VIAFID ORCID Logo  ; Poniman, Meliawati 3 ; Eggink, Dirk 4 ; Reusken, Chantal 4   VIAFID ORCID Logo  ; de Bree, Godelieve J. 5 ; Sanders, Rogier W. 3   VIAFID ORCID Logo  ; van Gils, Marit J. 3   VIAFID ORCID Logo  ; Heck, Albert J. R. 1   VIAFID ORCID Logo 

 University of Utrecht, Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands (GRID:grid.5477.1) (ISNI:0000000120346234); Netherlands Proteomic Center, Utrecht, The Netherlands (GRID:grid.5477.1) 
 University of Amsterdam, Amsterdam Institute for Infection and Immunity, Department of Medical Microbiology, Amsterdam UMC, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262); Vrije Universiteit Amsterdam, Amsterdam Institute for Infection and Immunity, Department of Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands (GRID:grid.12380.38) (ISNI:0000 0004 1754 9227) 
 University of Amsterdam, Amsterdam Institute for Infection and Immunity, Department of Medical Microbiology, Amsterdam UMC, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262) 
 National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands (GRID:grid.31147.30) (ISNI:0000 0001 2208 0118) 
 Vrije Universiteit Amsterdam, Amsterdam Institute for Infection and Immunity, Department of Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands (GRID:grid.12380.38) (ISNI:0000 0004 1754 9227) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2724927515
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.